MX2019004410A - Particulas citotoxicas. - Google Patents
Particulas citotoxicas.Info
- Publication number
- MX2019004410A MX2019004410A MX2019004410A MX2019004410A MX2019004410A MX 2019004410 A MX2019004410 A MX 2019004410A MX 2019004410 A MX2019004410 A MX 2019004410A MX 2019004410 A MX2019004410 A MX 2019004410A MX 2019004410 A MX2019004410 A MX 2019004410A
- Authority
- MX
- Mexico
- Prior art keywords
- cytotoxic particles
- cytotoxic
- particles
- core
- receptorson
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se refiere a partículas citotóxicas para la terapia del cáncer que incluyen un núcleo y una pluralidad de dominios variables dispuestos en el núcleo para la unión a los receptores P2X7 en una célula cancerosa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016904292A AU2016904292A0 (en) | 2016-10-21 | Cytotoxic particles | |
PCT/AU2017/050885 WO2018071959A1 (en) | 2016-10-21 | 2017-08-18 | Cytotoxic particles |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019004410A true MX2019004410A (es) | 2019-09-26 |
Family
ID=62018376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019004410A MX2019004410A (es) | 2016-10-21 | 2017-08-18 | Particulas citotoxicas. |
Country Status (9)
Country | Link |
---|---|
US (2) | US11260131B2 (es) |
EP (1) | EP3528789A4 (es) |
JP (1) | JP7127021B2 (es) |
CN (1) | CN109862883A (es) |
AU (1) | AU2017346936B2 (es) |
BR (1) | BR112019007895A8 (es) |
CA (1) | CA3035835A1 (es) |
MX (1) | MX2019004410A (es) |
WO (1) | WO2018071959A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107614528A (zh) * | 2015-04-02 | 2018-01-19 | 生物权威(英国)有限公司 | 疼痛治疗 |
CN117881421A (zh) * | 2021-09-01 | 2024-04-12 | 生物权威(澳大利亚)有限责任公司 | 用于刺激免疫活性的方法和组合物 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPP991199A0 (en) | 1999-04-21 | 1999-05-13 | University Of Sydney, The | Methods for diagnosing pre-cancerous and cancerous conditions |
AUPQ968700A0 (en) | 2000-08-28 | 2000-09-21 | Intreat Pty Limited | Treatment of urinary incontinence |
US20040067196A1 (en) * | 2000-10-11 | 2004-04-08 | Brunke Karen J. | Targeted therapeutic lipid constructs |
AUPR201500A0 (en) | 2000-12-11 | 2001-01-11 | Biosceptre Pty Ltd | Methods for identifying pre-neoplastic and neoplastic states in mammals |
ES2320421T3 (es) | 2001-01-17 | 2009-05-22 | Intreat Pty Limited | Anticuerpos para el diagnostico de un receptor p2x7 no funcional y el tratamiento de canceres y otras afecciones. |
NZ565994A (en) | 2001-09-03 | 2010-02-26 | Intreat Pty Ltd | Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions |
SE0301109D0 (sv) * | 2003-04-14 | 2003-04-14 | Mallen Huang | Nucleotide vaccine composition |
CN101484139A (zh) * | 2006-05-15 | 2009-07-15 | 乔治敦大学 | 用于治疗剂或诊断剂的全身施用的抗体或抗体片段靶向的免疫脂质体的制备及其应用 |
WO2008043145A1 (en) | 2006-10-10 | 2008-04-17 | Biosceptre International Limited | Hybridomas producing antibodies against non functional p2x7 receptor |
WO2008043146A1 (en) | 2006-10-10 | 2008-04-17 | Biosceptre International Limited | Antibodies against non functional p2x7 receptor |
ES2619681T3 (es) | 2007-09-14 | 2017-06-26 | Biosceptre (Aust) Pty Ltd | Novedosos epítopos P2X7 |
NZ583896A (en) | 2007-09-14 | 2011-05-27 | Biosceptre Int Ltd | Purinergic (p2x) receptors in extra-cellular body fluid |
CN101878229A (zh) * | 2007-09-28 | 2010-11-03 | 巴塞尔大学医院 | 用于治疗癌症的免疫脂质体 |
ES2610225T3 (es) | 2008-07-04 | 2017-04-26 | Biosceptre (Aust) Pty Ltd | Péptidos y epítopos anti P2X7 |
CN101536982B (zh) * | 2009-04-27 | 2011-11-09 | 中国人民解放军第二军医大学 | Trastuzumab修饰的包裹毒素蛋白的PEG化免疫脂质体及其制备与应用 |
WO2011020155A1 (en) | 2009-08-20 | 2011-02-24 | Biosceptre International Limited | Anti p2x7 receptor antibodies and fragments thereof |
EP3321285B1 (en) | 2009-12-24 | 2019-04-24 | Biosceptre (Aust) Pty Ltd | Antibodies to non-functional oligomeric p2x7 receptors |
ES2656971T3 (es) * | 2010-09-10 | 2018-03-01 | Biosceptre (Aust) Pty Ltd | Tratamientos para el cáncer en animales de compañía con un anticuerpo anti P2X7 |
BR112013033974A2 (pt) * | 2011-07-01 | 2017-02-14 | Biosceptre Int Ltd | terapia de combinação |
CN102429868A (zh) * | 2011-12-09 | 2012-05-02 | 南开大学 | 具有肿瘤靶向、体内示踪和治疗作用的脂质体药物组合物及制备方法 |
CN107614528A (zh) | 2015-04-02 | 2018-01-19 | 生物权威(英国)有限公司 | 疼痛治疗 |
-
2017
- 2017-08-18 JP JP2019520598A patent/JP7127021B2/ja active Active
- 2017-08-18 EP EP17862514.1A patent/EP3528789A4/en active Pending
- 2017-08-18 CN CN201780063609.5A patent/CN109862883A/zh active Pending
- 2017-08-18 US US16/326,882 patent/US11260131B2/en active Active
- 2017-08-18 BR BR112019007895A patent/BR112019007895A8/pt active Search and Examination
- 2017-08-18 CA CA3035835A patent/CA3035835A1/en active Pending
- 2017-08-18 AU AU2017346936A patent/AU2017346936B2/en active Active
- 2017-08-18 WO PCT/AU2017/050885 patent/WO2018071959A1/en unknown
- 2017-08-18 MX MX2019004410A patent/MX2019004410A/es unknown
-
2022
- 2022-01-13 US US17/575,568 patent/US20220249692A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3528789A4 (en) | 2020-06-24 |
JP7127021B2 (ja) | 2022-08-29 |
AU2017346936A1 (en) | 2019-03-07 |
BR112019007895A2 (pt) | 2019-07-02 |
US20190201545A1 (en) | 2019-07-04 |
BR112019007895A8 (pt) | 2022-12-20 |
US20220249692A1 (en) | 2022-08-11 |
CN109862883A (zh) | 2019-06-07 |
WO2018071959A1 (en) | 2018-04-26 |
CA3035835A1 (en) | 2018-04-26 |
EP3528789A1 (en) | 2019-08-28 |
AU2017346936B2 (en) | 2022-10-06 |
JP2019533677A (ja) | 2019-11-21 |
US11260131B2 (en) | 2022-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018008514A (es) | Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones cancerosas. | |
AU359077S (en) | A cover of a blending system | |
MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
EP3548064A4 (en) | ANTI-HRS ANTIBODIES AND COMBINATION THERAPIES FOR THE TREATMENT OF CANCERS | |
IL262251B1 (en) | New anti-syrap antibodies and their medical applications | |
HK1258319A1 (zh) | 癌症療法 | |
GB201611535D0 (en) | Methods and compositions for treating cancer with siglec-9 activity modulators | |
IL260474B (en) | Antibodies specific to cadherin-17 and cytotoxic cells for cancer treatment | |
IL246607B (en) | Improved cellular preparations and methods for cancer treatment | |
ZA202102740B (en) | Anti-liv1 immune cell cancer therapy | |
MX2017012553A (es) | Compuestos espirociclicos. | |
ZA202102745B (en) | Anti-ptk7 immune cell cancer therapy | |
SG11202106295WA (en) | Compositions and methods for cancer therapy | |
MX2018011219A (es) | Trail diseñado por ingenieria para terapia de cancer. | |
MX2019004410A (es) | Particulas citotoxicas. | |
EP3245204A4 (en) | Small molecules for the treatment of primary cancer and cancer metastasis | |
EP3532638A4 (en) | TARGETING MICROARN-101-3 P IN CARCINOTHERAPY | |
GB201901427D0 (en) | Cancer therapies | |
EP3548070A4 (en) | METHODS AND COMPOSITIONS FOR ANTI-CANCER THERAPY | |
EP3426804A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHEMOTHERAPY RESISTANT CANCER | |
GB201704909D0 (en) | Cancer therapy | |
GB201711855D0 (en) | Cancer therapy | |
IL274866A (en) | Preparations and methods for the treatment of cancer | |
GB201711250D0 (en) | Cancer therapy | |
GB201710198D0 (en) | Cancer therapy |